Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2020.0297


Early and underway Precision Medicine trials and novel insights into regulatory networks for colorectal cancer.

Chee-Seng Ku, MD, PhD.


Rapid progress and integration of NGS and CRISPR/Cas9 technologies into early-phase and underway clinical trials highlight the beginning of clinical Cancer Precision Medicine (CPM). Moreover, the breakthrough combination of genome and transcriptome sequencing, editing and mapping including high-G providing now novel knowledge on how coding and non-coding mutation deregulate dynamic transcriptional networks and gene expression.
In this Perspective article, basic, translational and clinical integration applying these technologies are discussed with a patient-centric orientation for colorectal cancer.

(Citation: Gastric & Breast Cancer 2020; 15(1): 52-60)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 17 January 2020